Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Lipicard Technologies Limited - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Lipicard Technologies Limited - Product Pipeline Review - 2016', provides an overview of the Lipicard Technologies Limited's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Lipicard Technologies Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Lipicard Technologies Limited - The report provides overview of Lipicard Technologies Limited including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Lipicard Technologies Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Lipicard Technologies Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Lipicard Technologies Limited's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Lipicard Technologies Limited - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Lipicard Technologies Limited's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Lipicard Technologies Limited Snapshot 7 Lipicard Technologies Limited Overview 7 Key Information 7 Key Facts 7 Lipicard Technologies Limited - Research and Development Overview 8 Key Therapeutic Areas 8 Lipicard Technologies Limited - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Lipicard Technologies Limited - Pipeline Products Glance 13 Lipicard Technologies Limited - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 15 Lipicard Technologies Limited - Drug Profiles 16 gabafol 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 KeraKlear 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 LT-1121 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 LT-1123 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 LT-2121 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 LT-2221 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 LT-2223 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 LT-2321 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 LT-2322 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 LT-2323 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 LT-2421 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 LT-2423 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 LT-2521 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 LT-3121 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 LT-3122 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 LT-4121 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 LT-4122 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 LT-4123 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 LT-4124 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 LT-4125 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 LT-4126 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 LT-5121 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 LT-5122 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 LT-5221 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 LT-5222 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 LT-5223 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 LT-5321 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 LT-5322 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 LT-5323 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 LT-5421 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 LT-5423 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 LT-5521 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 peroxibrate 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 platrol 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 raviprofen 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 LT-6121 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Lipicard Technologies Limited - Pipeline Analysis 52 Lipicard Technologies Limited - Pipeline Products by Target 52 Lipicard Technologies Limited - Pipeline Products by Route of Administration 53 Lipicard Technologies Limited - Pipeline Products by Molecule Type 54 Lipicard Technologies Limited - Pipeline Products by Mechanism of Action 55 Lipicard Technologies Limited - Locations And Subsidiaries 56 Head Office 56 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables
Lipicard Technologies Limited, Key Information 7 Lipicard Technologies Limited, Key Facts 7 Lipicard Technologies Limited - Pipeline by Indication, 2016 9 Lipicard Technologies Limited - Pipeline by Stage of Development, 2016 11 Lipicard Technologies Limited - Monotherapy Products in Pipeline, 2016 12 Lipicard Technologies Limited - Preclinical, 2016 13 Lipicard Technologies Limited - Discovery, 2016 15 Lipicard Technologies Limited - Pipeline by Target, 2016 52 Lipicard Technologies Limited - Pipeline by Route of Administration, 2016 53 Lipicard Technologies Limited - Pipeline by Molecule Type, 2016 54 Lipicard Technologies Limited - Pipeline Products by Mechanism of Action, 2016 55
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.